What Do Analysts Think About Puma Biotechnology (PBYI)?

Core Insights - Puma Biotechnology, Inc. (NASDAQ:PBYI) is considered one of the best affordable biotech stocks to invest in currently [1] - The company reported fiscal Q2 2025 results with product revenue net reaching $49.2 million, an increase from $44.4 million in fiscal Q2 2024 [1] - The product revenue net for the first six months of 2025 was $92.3 million, up from $84.6 million in the same period in 2024 [2] Analyst Ratings - TD Cowen analyst Marc Frahm maintained a Hold rating on Puma Biotechnology, Inc. and set a price target of $4.00 [2] - Barclays analyst Gena Wang maintained a Sell rating on Puma Biotechnology, Inc. with a price target of $2.00 [3] Company Focus - Puma Biotechnology, Inc. is a biopharmaceutical company focused on acquiring and developing innovative products for cancer treatment [3] - The company aims to in-license drug candidates that are in the process of or have already undergone initial clinical testing for cancer treatment [4]